Asset profile
LN-145
Cell therapy
Evidence outlook · results not reported
NCT03645928 · Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung...
The lead study uses a design that frequently fails to replicate under controlled conditions, and its results have not been reported. This tier describes the design, not an outcome.
NCT03645928: This open-label study gave tumor-infiltrating lymphocyte therapy (lifileucel or LN-145), alone or combined with checkpoint inhibitors, to patients with advanced melanoma, head-and-neck cancer or non-small-cell lung cancer across multiple non-randomized treatment cohorts, with objective response rate as the primary measure. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
68 competitors in this universe: 5 direct rivals (same mechanism and indication), 3 same-class, 60 same-indication; 61 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| LN-145: this drug | Phase 2 | Cell therapy | No discrete molecular target | ||
| Olvimulogene Nanivacirepvec | Phase 3 | Oncolytic Virus | No discrete molecular target | ||
| RP1 | Phase 2 | Biologic (subtype unspecified) | No discrete molecular target | ||
| KB707 | Phase 1/2 | Gene therapy / editing | No discrete molecular target | ||
| SL-28 | Phase 1/2 | Biologic (subtype unspecified) | No discrete molecular target | ||
| KB-GDT-01 | Phase 1 | Biologic (subtype unspecified) | No discrete molecular target | ||
| ALF201 | Phase 2 | Cell therapy | No discrete molecular target | ||
| Adipose-Derived MSC Clusters (S.Biomedics) | Phase 1/2 | Cell therapy | No discrete molecular target | ||
| BGC101 | Phase 1/2 | Cell therapy | No discrete molecular target | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| Amivantamab | Approved | Multispecific antibody | EGFR x c-MET | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | ||
| BAY2927088 (Hyrnuo) | Approved | Small molecule | HER2 (ERBB2) exon 20 insertions and point mutations; also mutant-selective EGFR |
…and 53 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (2)
April 2027 (1)
What to watch
May 2027 (1)
What to watch
2028 (1)
September 2028 (1)
What to watch
2030 (1)
December 2030 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.